MTOR and nonpapillary renal cell carcinoma: Molecular targeting therapy such as VEGF-tyrosine kinase inhibitors9 and mammalian target of rapamycin (mTOR) inhibitors 10,11 is used to treat advanced ccRCC and metastatic ccRCC patients.